^
    Back
    Association details:
    Biomarker:STRN-ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Thorac Cancer
    Title:

    Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report

    Published date:
    05/07/2021
    Excerpt:
    Here, we report a rare case of striatin (STRN)-ALK-positive NSCLC showing primary resistance to first-line therapy alectinib and limited clinical activity of crizotinib in the alectinib-resistant setting.
    DOI:
    10.1111/1759-7714.13983
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Thorac Oncol
    Title:

    Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC

    Published date:
    11/25/2020
    Excerpt:
    CONTRADICTING EVIDENCE: In total, 3787 NSCLC samples were analyzed....five patients harboring genomic-positive but RNA and protein–negative ALK or ROS1 fusion who received crizotinib had PD within 1 to 3 months of therapy
    DOI:
    10.1016/j.jtho.2020.10.156
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Mayo Clin Proc
    Title:

    A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib

    Excerpt:
    ...Chinese male originally diagnosed with “stage Ib lung adenocarcinoma” showed metastases...identified a rare fusion gene of ALK and Striatin (STRN)...The patient was treated with crizotinib and showed excellent clinical, radiographic, and molecular response...first clinical evidence involving advanced NSCLC due to a rare STRN-ALK fusion and has been effectively treated with crizotinib.
    DOI:
    10.1016/j.mayocpiqo.2017.04.003